Status: Recruiting
BGT007H Cells for the Treatment of Refractory Digestive System Tumors
This is an exploratory clinical study evaluating the safety and initial efficacy of BGT007H injection in the treatment of recurrent/metastatic/refractory digestive system tumors.
Participants needed: 14
Trial details
Phase: Early Phase 1Age: 18-70Biological sex: AllType: InterventionalSponsor: The Affiliated Hospital of Xuzhou Medical UniversityUpdated: Oct 27, 2023Locations: 1
Eligibility criteria
Voluntarily sign a written informed consent; [+10]
Active central nervous system metastases (except those stable after treatment); [+15]